multiple sclerosis

Showing 15 posts of 105 posts found.

roche_close

Roche’s Ocrevus gets the go ahead in Europe for two forms of MS

January 12, 2018
Medical Communications, Sales and Marketing Europe, European Commission, Ocrevus, Roche, multiple sclerosis, pharma

Roche has revealed that its multiple sclerosis (MS) drug Ocrevus (ocrelizumab) has been awarded marketing approval in Europe by the …

NICE recommends Novartis’ Extavia for MS, but knocks back a raft of other beta interferons

December 20, 2017
Research and Development, Sales and Marketing Extavia, MS, NICE, Novartis, beta interferon, multiple sclerosis

NICE has revealed that it has passed draft guidance that recommends Novartis’ Extavia (interferon beta 1b) for the treatment of …

roche_dark_0

EMA recommends approval of Roche’s Ocrevus in relapsing forms of multiple sclerosis

November 13, 2017
Sales and Marketing MS, Ocrevus, Roche, multiple sclerosis, pharma

Roche has revealed that its humanised monoclonal antibody Ocrevus (ocrelizumab) received a positive recommendation from the Committee for Medical Products …

nhs_sign

NHS England seals access deals with big pharma for breast cancer and MS

November 9, 2017
Sales and Marketing Cancer, Mavenclad, Merck, NHS, NHS England, NICE, Perjeta, Roche, Simon Stevens, breast cancer, multiple sclerosis

NHS England has entered into a commercial agreement with Merck which aims to provide access to innovative treatments for both …

nerves

Breakthrough study could revolutionise MS treatment

October 13, 2017
Medical Communications, Research and Development biotech, drugs, multiple sclerosis, pharma, pharmaceutical

The results of a study from the University of California, San Francisco will be welcomed with a certain excitement from …

roche

Roche chalks up Swiss approval for multiple sclerosis drug Ocrevus

September 28, 2017
Sales and Marketing Ocrevus, Roche, multiple sclerosis, pharma, pharmaceutical

Roche has announced that its drug Ocrevus (ocrelizumab) has received marketing approval in Switzerland for the treatment of active relapsing …

novartis_side_building

Novartis celebrates success of Gilenya in paediatric multiple sclerosis

September 5, 2017
Manufacturing and Production, Research and Development MS, Novartis, gilenya, health, multiple sclerosis, pharma, pharmaceuticals

Novartis has announced results of its Phase 3 study investigating the safety and efficacy of Gilenya (fingolimod) , finding that …

merck_kgaa_pyramid_use_with_credit

Seven years later, EC gives approval for Merck KGaA’s MS drug

August 25, 2017
Medical Communications, Sales and Marketing Mavenclad, Merck KGaA, biotech, drugs, multiple sclerosis, pharma, pharmaceutical

In 2011, Merck KGaA had all but given up on its MS drug after having been knocked back by both …

shutterstock_236161768

Novartis launches first large-scale smartphone-based study in multiple sclerosis

August 23, 2017
Research and Development MS, Novartis, life sciences, multiple sclerosis, pharma, pharmaceuticals

Novartis has launched what it claims is the first large-scale mobile research study which will gather data on multiple sclerosis …

francesa

US Congressmen accuse Teva of price hikes over 1,000%

August 21, 2017
Sales and Marketing Copaxone, Teva, life sciences, medicine, multiple sclerosis, pharma, pharmaceutical, price hiking

A pair of US Congressmen have fired allegations at Israeli drugmaker Teva accusing the firm of hiking the price of …

A example of a myelinated neuron

Old antibiotic offers potential cost-effective MS treatment

June 2, 2017
Medical Communications, Research and Development Myelin, multiple sclerosis

The cost of treatment for multiple sclerosis varies wildly, in the UK treatment can cost £56,000 per year while in …

folder

Common treatment for MS revealed to have potential adverse reactions

May 16, 2017
Manufacturing and Production, Research and Development MS, multiple sclerosis

Beta interferons are a common treatment used to manage multiple sclerosis. The treatment works by reducing and preventing the inflammation …

pills-384846_960_720

£6 million statin study to determine potential therapeutic use in MS

May 9, 2017
Manufacturing and Production, Research and Development multiple sclerosis, statins

A large study will take place in the UK to determine whether statins, commonly prescribed to combat “bad cholesterol”, are …

shutterstock_311949818

Breakthrough multiple sclerosis research sheds light on cause of the disease

April 24, 2017
Research and Development, Sales and Marketing multiple sclerosis

Researchers from the Universities of Exeter and Alberta have identified a protein in the brain which they believe could be …

celgene_1_02

Celgene’s potential blockbuster gets positive Phase 3 results in multiple sclerosis

February 20, 2017
Research and Development, Sales and Marketing Celgene, multiple sclerosis

Celgene’s drug to treat patients suffering with relapsing multiple sclerosis (RMS) was given a boost by positive Phase 3 trial …

Latest content